BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15304486)

  • 21. Cooperation of PU.1 With IRF8 and NFATc1 Defines Chromatin Landscapes During RANKL-Induced Osteoclastogenesis.
    Izawa N; Kurotaki D; Nomura S; Fujita T; Omata Y; Yasui T; Hirose J; Matsumoto T; Saito T; Kadono Y; Okada H; Miyamoto T; Tamura T; Aburatani H; Tanaka S
    J Bone Miner Res; 2019 Jun; 34(6):1143-1154. PubMed ID: 30721543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL.
    Huang H; Ryu J; Ha J; Chang EJ; Kim HJ; Kim HM; Kitamura T; Lee ZH; Kim HH
    Cell Death Differ; 2006 Nov; 13(11):1879-91. PubMed ID: 16498455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multifunctional protein fused in sarcoma (FUS) is a coactivator of microphthalmia-associated transcription factor (MITF).
    Bronisz A; Carey HA; Godlewski J; Sif S; Ostrowski MC; Sharma SM
    J Biol Chem; 2014 Jan; 289(1):326-34. PubMed ID: 24257758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dimer formation of receptor activator of nuclear factor kappaB induces incomplete osteoclast formation.
    Iwamoto K; Miyamoto T; Sawatani Y; Hosogane N; Hamaguchi I; Takami M; Nomiyama K; Takagi K; Suda T
    Biochem Biophys Res Commun; 2004 Dec; 325(1):229-34. PubMed ID: 15522223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts.
    Takayanagi H; Kim S; Koga T; Nishina H; Isshiki M; Yoshida H; Saiura A; Isobe M; Yokochi T; Inoue J; Wagner EF; Mak TW; Kodama T; Taniguchi T
    Dev Cell; 2002 Dec; 3(6):889-901. PubMed ID: 12479813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-kappaB-dependent, CD40-mediated bone destruction in rheumatoid arthritis.
    Lee HY; Jeon HS; Song EK; Han MK; Park SI; Lee SI; Yun HJ; Kim JR; Kim JS; Lee YC; Kim SI; Kim HR; Choi JY; Kang I; Kim HY; Yoo WH
    Arthritis Rheum; 2006 Jun; 54(6):1747-58. PubMed ID: 16736517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation.
    Sundaram K; Nishimura R; Senn J; Youssef RF; London SD; Reddy SV
    Exp Cell Res; 2007 Jan; 313(1):168-78. PubMed ID: 17084841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling.
    Mansky KC; Sankar U; Han J; Ostrowski MC
    J Biol Chem; 2002 Mar; 277(13):11077-83. PubMed ID: 11792706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors.
    Pang M; Rodríguez-Gonzalez M; Hernandez M; Recinos CC; Seldeen KL; Troen BR
    J Cell Biochem; 2019 Aug; 120(8):12382-12392. PubMed ID: 30816596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y; Okahashi N; Koseki T; Itoh K; Udagawa N; Hashimoto O; Sugino H; Noguchi T; Nishihara T
    J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium/calmodulin-dependent kinase activity is required for efficient induction of osteoclast differentiation and bone resorption by receptor activator of nuclear factor kappa B ligand (RANKL).
    Ang ES; Zhang P; Steer JH; Tan JW; Yip K; Zheng MH; Joyce DA; Xu J
    J Cell Physiol; 2007 Sep; 212(3):787-95. PubMed ID: 17477372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective co-activator recruitment in osteoclasts from microphthalmia-oak ridge mutant mice.
    Sharma SM; Sif S; Ostrowski MC; Sankar U
    J Cell Physiol; 2009 Jul; 220(1):230-7. PubMed ID: 19288495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
    Rahman MM; Kukita A; Kukita T; Shobuike T; Nakamura T; Kohashi O
    Blood; 2003 May; 101(9):3451-9. PubMed ID: 12511413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
    Hyeon S; Lee H; Yang Y; Jeong W
    Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K.
    Lange AW; Yutzey KE
    Dev Biol; 2006 Apr; 292(2):407-17. PubMed ID: 16680826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
    Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
    J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms involved in enhancement of osteoclast formation by activin-A.
    Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
    J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.